Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Karyopharm Therapeutics Inc.KPTI · Entity 781 | EVP, Chief Medical Officer | February 17, 2022 | February 22, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Karyopharm Therapeutics Inc.
Report date February 17, 2022 · Filed February 22, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 129,450 |
Reported balance
After 2022-02-17 transaction · row 1
1 source rowRow 1 · 2022-02-17 · Sale · Disposed 1,306 · Balance 129,450 F1: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. F2: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 17, 2022 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.
F2: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 17, 2022 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2022 Filed Feb 22, 2022 21:19 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 1,306 | $12.12 | $15,833.16 |
DisclosureSEC source: 0001209191-22-011650 · doc4.xml · nonDerivative · entry 1 Shah Jatin · CIK 0001782186 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,450 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 17, 2022 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| February 07, 2022 Filed Feb 9, 2022 22:27 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 1,704 | $9.86 | $16,804.85 |
DisclosureSEC source: 0001209191-22-008130 · doc4.xml · nonDerivative · entry 1 Shah Jatin · CIK 0001782186 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,756 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 7, 2022 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees. F3 · balance_after: Includes 1,323 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan on October 31, 2021. Read SEC document |
| July 12, 2021 Filed Jul 13, 2021 22:21 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Tax withholdingCommon Stock | 665 | $9.73 | $6,470.45 |
DisclosureSEC source: 0001209191-21-046589 · doc4.xml · nonDerivative · entry 1 Shah Jatin · CIK 0001782186 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,137 F1 · shares: Represents shares withheld to satisfy the reporting person's tax obligation in connection with the vesting of 2,413 restricted stock units on July 11, 2021. Read SEC document |
| May 07, 2021 Filed May 11, 2021 12:58 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | PurchaseCommon Stock | 23,250 | $8.60 | $199,991.85 |
DisclosureSEC source: 0001209191-21-031481 · doc4.xml · nonDerivative · entry 1 Shah Jatin · CIK 0001782186 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,802 F1 · price: Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $8.5850 to $8.61, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 861 shares acquired by the reporting person under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan on April 30, 2021. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 01:17 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantStock Option (right to buy) · Derivative | 59,968 | $0.00 Strike: $14.56 | $0.00 |
DisclosureSEC source: 0001209191-21-015487 · doc4.xml · derivative · entry 2 Shah Jatin · CIK 0001782186 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,968 Underlying: Common Stock · 59,968 shares Expires 2031-02-24 F3 · derivative.exercise_date: This option was granted on February 25, 2021 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 25, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 01:17 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantCommon Stock | 22,013 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-015487 · doc4.xml · nonDerivative · entry 1 Shah Jatin · CIK 0001782186 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,691 F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 25, 2022. F2 · balance_after: The reporting person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 22,013 newly awarded RSUs, 33,887 RSUs previously reported in Table II, and 51,791 shares of common stock. Read SEC document |
| February 18, 2021 Filed Feb 23, 2021 01:12 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 1,186 | $14.83 | $17,589.80 |
DisclosureSEC source: 0001209191-21-012968 · doc4.xml · nonDerivative · entry 1 Shah Jatin · CIK 0001782186 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,791 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 18, 2021 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 23:48 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionRestricted Stock Units · Derivative | 4,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-011494 · doc4.xml · derivative · entry 3 Shah Jatin · CIK 0001782186 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,700 Underlying: Common Stock · 4,850 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. F4 · derivative.exercise_date: On February 15, 2019, the reporting person was granted 19,400 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. F4 · derivative.expiration_date: On February 15, 2019, the reporting person was granted 19,400 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 23:48 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 4,850 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-011494 · doc4.xml · nonDerivative · entry 2 Shah Jatin · CIK 0001782186 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,977 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. Read SEC document |
| February 11, 2021 Filed Feb 17, 2021 23:48 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 1,748 | $15.52 | $27,127.39 |
DisclosureSEC source: 0001209191-21-011494 · doc4.xml · nonDerivative · entry 1 Shah Jatin · CIK 0001782186 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,127 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 11, 2021 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 02:56 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionRestricted Stock Units · Derivative | 5,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009138 · doc4.xml · derivative · entry 2 Shah Jatin · CIK 0001782186 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,950 Underlying: Common Stock · 5,650 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. F3 · derivative.exercise_date: On February 5, 2020, the reporting person was granted 22,600 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 5, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. F3 · derivative.expiration_date: On February 5, 2020, the reporting person was granted 22,600 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 5, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 02:56 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 5,650 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-009138 · doc4.xml · nonDerivative · entry 1 Shah Jatin · CIK 0001782186 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. F2 · balance_after: Includes 996 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan on April 30, 2020. Read SEC document |
| July 15, 2020 Filed Nov 5, 2020 01:16 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 589 | $19.46 | $11,461.94 |
DisclosureSEC source: 0001209191-20-057052 · doc4.xml · nonDerivative · entry 2 Shah Jatin · CIK 0001782186 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,229 F2 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. F3 · balance_after: Includes 646 shares acquired by the reporting person under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan on October 31, 2020. Read SEC document |
| July 11, 2020 Filed Nov 5, 2020 01:16 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionRestricted Stock Units · Derivative | 2,413 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-057052 · doc4.xml · derivative · entry 3 Shah Jatin · CIK 0001782186 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,237 Underlying: Common Stock · 2,413 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. F4 · derivative.exercise_date: On July 11, 2019, the reporting person was granted 9,650 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on July 11, 2020. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. F4 · derivative.expiration_date: On July 11, 2019, the reporting person was granted 9,650 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on July 11, 2020. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. Read SEC document |
| July 11, 2020 Filed Nov 5, 2020 01:16 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 2,413 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-057052 · doc4.xml · nonDerivative · entry 1 Shah Jatin · CIK 0001782186 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,172 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 22:58 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 1,375 | $16.48 | $22,662.61 |
DisclosureSEC source: 0001209191-20-011697 · doc4.xml · nonDerivative · entry 1 Shah Jatin · CIK 0001782186 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,759 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 19, 2020 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| February 15, 2020 Filed Feb 19, 2020 23:16 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionRestricted Stock Units · Derivative | 4,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-010762 · doc4.xml · derivative · entry 2 Shah Jatin · CIK 0001782186 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,550 Underlying: Common Stock · 4,850 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. F3 · derivative.exercise_date: On February 15, 2019, the reporting person was granted 19,400 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2020. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any an event within 30 days of such date. F3 · derivative.expiration_date: On February 15, 2019, the reporting person was granted 19,400 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on February 15, 2020. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any an event within 30 days of such date. Read SEC document |
| February 15, 2020 Filed Feb 19, 2020 23:16 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 4,850 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-010762 · doc4.xml · nonDerivative · entry 1 Shah Jatin · CIK 0001782186 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,134 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. F2 · balance_after: Includes 2,659 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:20 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantRestricted Stock Units · Derivative | 22,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007514 · doc4.xml · derivative · entry 2 Shah Jatin · CIK 0001782186 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,600 Underlying: Common Stock · 22,600 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 5, 2021, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 5, 2021, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:20 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantStock Option (right to buy) · Derivative | 60,600 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007514 · doc4.xml · derivative · entry 1 Shah Jatin · CIK 0001782186 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,600 Underlying: Common Stock · 60,600 shares Expires 2030-02-04 F1 · derivative.exercise_date: This option was granted on February 5, 2020. The shares underlying this option vest as to 25% of the shares on February 5, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| July 11, 2019 Filed Jul 15, 2019 20:05 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantRestricted Stock Units · Derivative | 9,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-042055 · doc4.xml · derivative · entry 2 Shah Jatin · CIK 0001782186 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,650 Underlying: Common Stock · 9,650 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning July 11, 2020, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as possible following each vesting date, but in any event within 30 days of such date. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning July 11, 2020, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as possible following each vesting date, but in any event within 30 days of such date. Read SEC document |
| July 11, 2019 Filed Jul 15, 2019 20:05 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantStock Option (right to buy) · Derivative | 25,700 | $0.00 Strike: $7.61 | $0.00 |
DisclosureSEC source: 0001209191-19-042055 · doc4.xml · derivative · entry 1 Shah Jatin · CIK 0001782186 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,700 Underlying: Common Stock · 25,700 shares Expires 2029-07-10 F1 · derivative.exercise_date: This option was granted on July 11, 2019. The shares underlying this option vest as to 25% of the shares on July 11, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.